In this systematic review and meta‐analysis from available RCTs, we have evaluated the efficacy and safety outcomes in patients with type 2 diabetes comparing the combination of SGLT2 and RAAS inhibitors with SGLT2‐Is alone. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.